Cargando…

Benefits and harms of lung cancer screening in HIV-infected individuals with CD4(+) cell count at least 500 cells/μl

OBJECTIVE: Lung cancer is the leading cause of non-AIDS-defining cancer deaths among HIV-infected individuals. Although lung cancer screening with low-dose computed tomography (LDCT) is endorsed by multiple national organizations, whether HIV-infected individuals would have similar benefit as uninfe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Chung Yin, Sigel, Keith, Criss, Steven D., Sheehan, Deirdre F., Triplette, Matthew, Silverberg, Michael J., Henschke, Claudia I., Justice, Amy, Braithwaite, R. Scott, Wisnivesky, Juan, Crothers, Kristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991188/
https://www.ncbi.nlm.nih.gov/pubmed/29683843
http://dx.doi.org/10.1097/QAD.0000000000001818
_version_ 1783329752337088512
author Kong, Chung Yin
Sigel, Keith
Criss, Steven D.
Sheehan, Deirdre F.
Triplette, Matthew
Silverberg, Michael J.
Henschke, Claudia I.
Justice, Amy
Braithwaite, R. Scott
Wisnivesky, Juan
Crothers, Kristina
author_facet Kong, Chung Yin
Sigel, Keith
Criss, Steven D.
Sheehan, Deirdre F.
Triplette, Matthew
Silverberg, Michael J.
Henschke, Claudia I.
Justice, Amy
Braithwaite, R. Scott
Wisnivesky, Juan
Crothers, Kristina
author_sort Kong, Chung Yin
collection PubMed
description OBJECTIVE: Lung cancer is the leading cause of non-AIDS-defining cancer deaths among HIV-infected individuals. Although lung cancer screening with low-dose computed tomography (LDCT) is endorsed by multiple national organizations, whether HIV-infected individuals would have similar benefit as uninfected individuals from lung cancer screening is unknown. Our objective was to determine the benefits and harms of lung cancer screening among HIV-infected individuals. DESIGN: We modified an existing simulation model, the Lung Cancer Policy Model, for HIV-infected patients. DATA SOURCES: Veterans Aging Cohort Study, Kaiser Permanente Northern California HIV Cohort, and medical literature. TARGET POPULATION: : HIV-infected current and former smokers. TIME HORIZON: : Lifetime. PERSPECTIVE: : Population. INTERVENTION: Annual LDCT screening from ages 45, 50, or 55 until ages 72 or 77 years. MAIN OUTCOME MEASURES: Benefits assessed included lung cancer mortality reduction and life-years gained; harms assessed included numbers of LDCT examinations, false-positive results, and overdiagnosed cases. RESULTS OF BASE-CASE ANALYSIS: For HIV-infected patients with CD4(+) cell count at least 500 cells/μl and 100% antiretroviral therapy adherence, screening using the Centers for Medicare & Medicaid Services criteria (age 55–77, 30 pack-years of smoking, current smoker or quit within 15 years of screening) would reduce lung cancer mortality by 18.9%, similar to the mortality reduction of uninfected individuals. Alternative screening strategies utilizing lower screening age and/or pack-years criteria increase mortality reduction, but require more LDCT examinations. LIMITATIONS: Strategies assumed 100% screening adherence. CONCLUSION: Lung cancer screening reduces mortality in HIV-infected patients with CD4(+) cell count at least 500 cells/μl, with a number of efficient strategies for eligibility, including the current Centers for Medicare & Medicaid Services criteria.
format Online
Article
Text
id pubmed-5991188
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-59911882018-06-19 Benefits and harms of lung cancer screening in HIV-infected individuals with CD4(+) cell count at least 500 cells/μl Kong, Chung Yin Sigel, Keith Criss, Steven D. Sheehan, Deirdre F. Triplette, Matthew Silverberg, Michael J. Henschke, Claudia I. Justice, Amy Braithwaite, R. Scott Wisnivesky, Juan Crothers, Kristina AIDS Epidemiology and Social OBJECTIVE: Lung cancer is the leading cause of non-AIDS-defining cancer deaths among HIV-infected individuals. Although lung cancer screening with low-dose computed tomography (LDCT) is endorsed by multiple national organizations, whether HIV-infected individuals would have similar benefit as uninfected individuals from lung cancer screening is unknown. Our objective was to determine the benefits and harms of lung cancer screening among HIV-infected individuals. DESIGN: We modified an existing simulation model, the Lung Cancer Policy Model, for HIV-infected patients. DATA SOURCES: Veterans Aging Cohort Study, Kaiser Permanente Northern California HIV Cohort, and medical literature. TARGET POPULATION: : HIV-infected current and former smokers. TIME HORIZON: : Lifetime. PERSPECTIVE: : Population. INTERVENTION: Annual LDCT screening from ages 45, 50, or 55 until ages 72 or 77 years. MAIN OUTCOME MEASURES: Benefits assessed included lung cancer mortality reduction and life-years gained; harms assessed included numbers of LDCT examinations, false-positive results, and overdiagnosed cases. RESULTS OF BASE-CASE ANALYSIS: For HIV-infected patients with CD4(+) cell count at least 500 cells/μl and 100% antiretroviral therapy adherence, screening using the Centers for Medicare & Medicaid Services criteria (age 55–77, 30 pack-years of smoking, current smoker or quit within 15 years of screening) would reduce lung cancer mortality by 18.9%, similar to the mortality reduction of uninfected individuals. Alternative screening strategies utilizing lower screening age and/or pack-years criteria increase mortality reduction, but require more LDCT examinations. LIMITATIONS: Strategies assumed 100% screening adherence. CONCLUSION: Lung cancer screening reduces mortality in HIV-infected patients with CD4(+) cell count at least 500 cells/μl, with a number of efficient strategies for eligibility, including the current Centers for Medicare & Medicaid Services criteria. Lippincott Williams & Wilkins 2018-06-19 2018-06-01 /pmc/articles/PMC5991188/ /pubmed/29683843 http://dx.doi.org/10.1097/QAD.0000000000001818 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Epidemiology and Social
Kong, Chung Yin
Sigel, Keith
Criss, Steven D.
Sheehan, Deirdre F.
Triplette, Matthew
Silverberg, Michael J.
Henschke, Claudia I.
Justice, Amy
Braithwaite, R. Scott
Wisnivesky, Juan
Crothers, Kristina
Benefits and harms of lung cancer screening in HIV-infected individuals with CD4(+) cell count at least 500 cells/μl
title Benefits and harms of lung cancer screening in HIV-infected individuals with CD4(+) cell count at least 500 cells/μl
title_full Benefits and harms of lung cancer screening in HIV-infected individuals with CD4(+) cell count at least 500 cells/μl
title_fullStr Benefits and harms of lung cancer screening in HIV-infected individuals with CD4(+) cell count at least 500 cells/μl
title_full_unstemmed Benefits and harms of lung cancer screening in HIV-infected individuals with CD4(+) cell count at least 500 cells/μl
title_short Benefits and harms of lung cancer screening in HIV-infected individuals with CD4(+) cell count at least 500 cells/μl
title_sort benefits and harms of lung cancer screening in hiv-infected individuals with cd4(+) cell count at least 500 cells/μl
topic Epidemiology and Social
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991188/
https://www.ncbi.nlm.nih.gov/pubmed/29683843
http://dx.doi.org/10.1097/QAD.0000000000001818
work_keys_str_mv AT kongchungyin benefitsandharmsoflungcancerscreeninginhivinfectedindividualswithcd4cellcountatleast500cellsml
AT sigelkeith benefitsandharmsoflungcancerscreeninginhivinfectedindividualswithcd4cellcountatleast500cellsml
AT crissstevend benefitsandharmsoflungcancerscreeninginhivinfectedindividualswithcd4cellcountatleast500cellsml
AT sheehandeirdref benefitsandharmsoflungcancerscreeninginhivinfectedindividualswithcd4cellcountatleast500cellsml
AT triplettematthew benefitsandharmsoflungcancerscreeninginhivinfectedindividualswithcd4cellcountatleast500cellsml
AT silverbergmichaelj benefitsandharmsoflungcancerscreeninginhivinfectedindividualswithcd4cellcountatleast500cellsml
AT henschkeclaudiai benefitsandharmsoflungcancerscreeninginhivinfectedindividualswithcd4cellcountatleast500cellsml
AT justiceamy benefitsandharmsoflungcancerscreeninginhivinfectedindividualswithcd4cellcountatleast500cellsml
AT braithwaiterscott benefitsandharmsoflungcancerscreeninginhivinfectedindividualswithcd4cellcountatleast500cellsml
AT wisniveskyjuan benefitsandharmsoflungcancerscreeninginhivinfectedindividualswithcd4cellcountatleast500cellsml
AT crotherskristina benefitsandharmsoflungcancerscreeninginhivinfectedindividualswithcd4cellcountatleast500cellsml